Medical Economics November 8, 2024
Mike Hollan

Key Takeaways

  • Trump’s administration may attempt to repeal the Affordable Care Act and the Inflation Reduction Act, affecting drug pricing.
  • Robert F. Kennedy Jr.’s potential role in health policy introduces uncertainty, especially regarding vaccine skepticism.
  • Industry leaders stress the importance of the FDA’s science-based, patient safety-focused standards.
  • The US healthcare system struggles with high costs and modest health outcomes compared to other countries.

A panel at the Financial Times’ 2024 Global Pharma and Biotech Summit in London analyzed what the re-election of Trump could mean to the pharmaceutical industry.

Donald Trump’s victory in the 2024 US presidential election is sure to have an impact on the pharmaceutical industry. During a panel at the Financial Times’ 2024 Global Pharma...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Conferences / Podcast, Congress / White House, Govt Agencies, Pharma, Pharma / Biotech, Trends
Related Articles:
6 key health policy areas to watch in the new year
Governing health care AI
PBM reform dropped in Congress' funding package
Trump's Picks for Top Health Jobs Not Just Team of Rivals but 'Team of Opponents'
Telehealth gets short extension, physician pay is cut in spending bill

Share This Article